UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.67 -0.39 (-0.49%) GOLD FUTURES
2,430.70 +13.30 (+0.55%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,716.77 +2,634.68 (+5.06%)
NKTX May 2024 2.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:32PM EDT. Market open.
| Previous close | 5.0700 |
| Open | 4.0000 |
| Bid | 3.9000 |
| Ask | 4.3000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 58 |
Simply Wall St.Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GuruFocus.com
Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis
Insights into Nkarta's Financial Health and Strategic Developments in Cell Therapy
GlobeNewswireNkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investmentsStrong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural kil
© 2024 Yahoo. All rights reserved.